Abstract Aims/hypothesis: The rapid degradation and clearance of glucagon-like peptide-1 (GLP-1) by the enzymes dipeptidyl peptidase-IV and neutral endopeptidase 24.11 are the main impediments to the development of GLP-1 as a potential glucose-lowering agent. In this study, new enzyme-resistant polyethylene glycol (PEG)-conjugated GLP-1 analogues were designed and examined for metabolic stability and biological potency. Materials and methods: Two mono-PEGylated GLP-1 analogues, N-terminally modified N-PEG/GLP-1 and Lys-modified Lys-PEG/GLP-1, were prepared. Stability was tested in plasma and tissue extracts. In vitro insulin release studies were performed using isolated rat pancreatic islets, while in vivo glycaemic responses were measured in db/db mice. Results: The half-life of Lys-PEG/GLP-1 was 40-, 10-and 28-fold longer than that of GLP-1 in plasma, liver and kidney homogenates, respectively. Lys-PEG/GLP-1 stimulated insulin secretion in the islets in a dose-and glucose-dependent manner, and was as potent as GLP-1. In contrast, N-PEG/GLP-1 showed extended metabolic stability but had significantly lower biological activity. The administration of Lys-PEG/GLP-1 (9 nmol/kg i.p.) to non-fasted db/db mice stabilised glycaemia (p<0.001), whereas GLP-1 (9 nmol/kg) only caused small changes in glucose level. During OGTT in fasted db/db mice, Lys-PEG/GLP-1 administered at 1, 3 and 9 nmol/kg (i.p.) reduced the glucose AUC 0-3h by 48.7±9.4, 55.0±2.9 and 63.4±2.5%, respectively, compared with placebo (p<0.01), whereas GLP-1 (9 nmol/kg) lowered the glucose level by 39.5±12.9% (p<0.01). Conclusions/interpretation: This study demonstrates that site-specific PEGylated GLP-1 analogues are resistant to degradation. The enhanced biological potencies of these analogues highlight their potential as new, GLP-1-like glucose-lowering agents.
Introduction
Glucagon-like peptide-1 (7-36)amide (GLP-1) is a polypeptide hormone secreted from L cells in the gastrointestinal tract in response to the ingestion of nutrients [1] . GLP-1 is viewed as a potent therapy for type 2 diabetes [2, 3] . However, its short circulating half-life means that high doses must be administered frequently, which limits its clinical application. The short half-live of GLP-1 is due to its rapid inactivation and clearance under physiological conditions by proteolytic enzymes such as dipeptidyl peptidase-IV (DPP-IV) [4] and neutral endopeptidase (NEP) 24.11 [5] .
We recently proposed a novel and potent enzymeresistant form of a site-specific polyethylene glycolated (PEGylated) GLP-1 [6] , and hypothesised that the covalent coupling of PEG to a specific site of GLP-1 would profoundly improve its enzymatic stability against DPP-IV and NEP 24.11, whilst retaining its biological activity. To this end, two series of mono-PEGylated GLP-1 analogues, N-terminally modified N-PEG/GLP-1 and Lys modified Lys-PEG/GLP-1, were prepared. These PEGylated GLP-1 analogues were clearly resistant to purified DPP-IV. Moreover, a pharmacokinetic evaluation in rats showed that the PEGylation process confers both an extended plasma half-life and a lower clearance rate, which result in S. Lee . Y. Byun College of Pharmacy, Seoul National University, San 56-1, Shillim-dong, Gwanak-gu, Seoul 151-742, South Korea a substantial improvement in the mean plasma residence time of GLP-1 after i.v. or s.c. administration.
In the present study we investigated the therapeutic potential of site-specific PEGylated GLP-1 by examining the impact of PEGylation on the biological activity and metabolic stability of GLP-1 in vitro, and its in vivo antihyperglycaemic effect in diabetic db/db mice.
Materials and methods
Preparation of mono-PEGylated GLP-1 The PEG molecule was mono-substituted covalently at the N-terminus position His 7 or at Lys
34
, and these analogues were designated N-PEG/GLP-1 and Lys-PEG/GLP-1, respectively [6] .
Enzymatic stability in plasma and tissue homogenates The peptides were incubated at 37°C with the individual plasma and tissue homogenates, as described previously [7] . Half-life was estimated as the time (min) needed for the peptide concentration to be reduced by 50%, as determined by calculating the peak area following reversed phase HPLC analysis.
Insulinotropic actions using isolated rat pancreatic islets Islets of Langerhans were isolated from male SpragueDawley rats, as described previously [8] . In vitro biological activity was evaluated by incubating 20 islets in 2 ml of Krebs Ringer bicarbonate HEPES buffer (containing 16.7 mmol/l glucose) containing the respective stimuli at various concentrations for 2 h at 37°C in an atmosphere of 95% air, 5% CO 2 . We carried out a separate set of experiments, incubating islets in the presence of 2.8, 5.5, 11.1 and 16.7 mmol/l glucose and 10 nmol/l of the respective peptides. Levels of insulin release were measured using radioimmunoassay kits (Insulin Kit; ICN Pharmaceuticals, Orangeburg, NY, USA).
Animals The animals were cared for according to the National Institutes of Health (NIH) guidelines for the care and use of laboratory animals (NIH publication 85-23, revised 1985). C57BL/6 db/db female mice (7-10 weeks old; from the Korea Research Institute of Bioscience and Biotechnology, Daejon, Korea) were used. In order to determine the biological potency of the peptides, nonfasted diabetic rodents were given a single i.p. injection of 9 nmol/kg of the peptides. Blood samples were collected from a tail vein, and blood glucose levels were determined using a one-touch blood glucose monitoring system (Glucocard II; Arkray, Kyoto, Japan).
OGTT Overnight-fasted diabetic mice received an i.p. injection of either saline or one of the peptides. At time −30 min, saline or 1, 3 or 9 nmol/kg of the peptides were administered i.p. At 0 min, 1.5 g/kg of glucose in PBS (10 mmol/l, pH 7.4) was given orally to each group (n=6). Blood glucose was monitored as described above.
Data analysis Data are expressed as means±SD in the text and as means±SEM in the figures. The Mann-Whitney non-parametric test or the t-test were used, depending on variances, to assess the statistical significance of differences. A p value of <0.05 was considered significant.
Results
Proteolytic stabilities GLP-1 was rapidly degraded in rat plasma, liver and kidney homogenates in vitro (t 1/2 values of 114±28, 6±0.5, 1±0.2 min, respectively). In contrast, Lys-PEG/GLP-1 and N-PEG/GLP-1 were found to have significantly longer half-lives than native GLP-1, with t 1/2 values in plasma, liver and kidney homogenates of 4471± 1822, 62±23 and 28±1 min for Lys-PEG/GLP-1, and 7560± 5635, 250±117 and 23±7 min for N-PEG/GLP-1, respectively (p<0.01 vs GLP-1).
In vitro biological activities In order to determine in vitro dose-response curves in terms of insulin released by GLP-1 and PEGylated GLP-1 analogues, peptide concentrations in media containing 16.7 mmol/l glucose were varied from 0.1-100 nmol/l ( , respectively, p=0.19) and was significantly more potent than N-PEG/GLP-1, which showed a 1.7±0.6-fold increase in insulin secretion per islet compared with the control, which contained no peptide.
Islets were cultured in different glucose concentrations (2.8, 5.5, 11.1 and 16.7 mmol/l) with or without the peptides (10 nmol/l) to determine if PEGylated GLP-1 could retain its glucose-dependent insulinotropic profile (Fig. 1b) . Islets cultured in 11.1 and 16.7 mmol/l of glucose showed rates of insulin secretion 4.0±1.5 and 8.2± 1.3 times higher than those observed in islets cultured in basal glucose (2.8 mmol/l), respectively. The addition of GLP-1 (10 nmol/l) further enhanced the level of insulin release by 14.8±2.8-fold and 21.8±5.2-fold at 11.1 and 16.7 mmol/l glucose, respectively. Lys-PEG/GLP-1 showed insulin secretion patterns that were comparable to those of native GLP-1 (increases of 11.0±2.2 and 17.1± 5.8-fold at 11.1 and 16.7 mmol/l glucose, respectively). N-PEG/GLP-1 exhibited a lower biological activity.
Glucodynamic profiles in vivo
To investigate the biological potency of PEGylated GLP-1 in vivo, equivalent doses (9 nmol/kg) of the peptides were administered to db/db mice by i.p. injection (Fig. 2a) , respectively). Dose-response relationships between GLP-1 or PEGylated GLP-1 and glucose tolerance were investigated (Fig. 2b) . The administration of GLP-1 at a dose of 1 or 3 nmol/kg did not appreciably improve glucose tolerance. However, GLP-1 at a dose of 9 nmol/kg showed enhanced glucose elimination. This was evident from reductions in the glucose level and the glucose AUC 0-3h (42. , respectively, p<0.01 vs saline). The administration of N-PEG/ GLP-1 did not alter blood glucose levels significantly.
Discussion
In this study we investigated the metabolic stability, biological activity and the acute effects of site-specific PEGylated Lys-PEG/GLP-1 as a potential replacement for GLP-1. We first investigated the impact of PEGylation on the metabolic stability of GPL-1 in vitro. It was hypothesised that conjugation of inert polymeric water-soluble substances on peptide surfaces could sterically hinder the approach of proteolytic enzymes [9] , and that this would substantially improve in vivo stability. In the present study, compared with GLP-1, N-PEG/GLP-1 and Lys-PEG/GLP-1 showed much longer half-lives in plasma and in liver and kidney homogenates.
The biological activity of PEGylated GLP-1 analogues was investigated in vitro using pancreatic islets. Lys-PEG/ GLP-1 was almost as potent at stimulating insulin secretion as GLP-1, and did so in a dose-and glucose-dependent manner. These findings suggest that the PEG molecule at lysine effectively protects GLP-1 from proteolytic enzyme attack without altering its biological activity. In contrast, N-PEG/GLP-1 showed improved stability but significantly lower biological activity compared with Lys-PEG/GLP-1.
In order to determine if the PEGylated GLP-1 analogues are potential treatments for type 2 diabetes, we evaluated the acute antihyperglycaemic effects by administering them by i.p. injection to diabetic db/db mice. Our findings show that Lys-PEG/GLP-1 produced the desired biological effect in a dose-dependent manner. Furthermore, Lys-PEG/ GLP-1 significantly reduced peak blood glucose levels after OGTT. This finding is further substantiated by our previous pharmacokinetic results in rats [6] . Taken with our enzyme-resistance results, Lys-PEG/GLP-1 shows greater longevity than GLP-1 in plasma under physiological conditions. The combination of augmented beta cell insulin secretion, increased insulin sensitivity (i.e. by OGTT) and improved half-life in plasma explain the durable glucoselowering effect of Lys-PEG/GLP-1. From this point of view, Lys-PEG/GLP-1 fulfilled all the features expected of a PEGylated GLP-1.
This study demonstrates that site-specific PEGylated GLP-1 analogues are resistant to degradation. In addition, their enhanced biological potencies highlight their potential as new GLP-1-like glucose-lowering agents.
